Newsletter Subject

Daily Headlines: Fat Grafting Improved Satisfaction with Reconstructed Breasts

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Mon, Jul 3, 2017 11:11 AM

Email Preheader Text

Daily Headlines July 3, 2017 CME/CE CME/CE CME/CE Additional Resources Industry Resources Recent Hea

Daily Headlines July 3, 2017 [Fat Grafting Improved Satisfaction with Reconstructed Breasts]( [Some Respond to Nivolumab After Melanoma Progression]( CME/CE [No Penicillin Allergy Found in Most Kids with Non-Specific Symptoms]( [Lymphopenia a Risk for PJP]( CME/CE [New Opioid Use in Older COPD Patients Tied to Higher CV Death Risk]( CME/CE Additional Resources [Diagnosis and Treatment of Relapsed Myeloma]( [AML: Beware of Pre-leukemic Clones Surviving Chemotherapy]( [Support for Omitting ALND in Early Breast Cancer]( Industry Resources [Relapsed Multiple Myeloma - Updated Treatment Option Info Learn About The Head-to-Head Data for this Relapsed MM Treatment Option]( [Renal Cancer Treatment - Official HCP Site A Once-Daily Oral Treatment For Advanced Renal Cell Carcinoma Patients]( [Site For Endocrinologists Low Testosterone Due To Certain Medical Conditions. Treatment Info]( Recent Headlines [What To Know About Going Part-Time]( [Healthcare Groups Push to Repeal IPAB by August Deadline]( [Doctors Shot in Bronx Hospital]( ['Talking and Lectures Don't Work': What We Heard This Week]( [PET/CT May Show Outcome Early in mCRPC]( CME/CE ADVERTISEMENT This Week's Survey [Senate Healthcare Bill: Hit or Miss?]( [Sometime after the July 4 holiday, the Senate will take up the]([GOP bill to repeal and replace the Affordable Care Act]( CME Spotlights [Can your pharmacist substitute your biologic? Is that OK?]( [Source: France Foundation]( [Playing The Offense In Advanced Basal Cell Carcinoma: A Team Approach To Treatment And Management]( [Source: RMEI Medical Education]( [Breast Cancer @POC w/Watson]( [Source: @Point of Care]( [MDS and Acute Myeloid Leukemia (MDS and AML) @Point of Care]( [Source: @Point of Care]( [Skin Cancers @Point of Care]( [Source: @Point of Care]( [Treatment of Platinum-Resistant Recurrent Ovarian Epithelial Cancer]( [Source: Projects in Knowledge, Inc.]( [Treatment of Recurrent Stage IIIB Cervical Adenoma]( [Source: Projects In Knowledge, Inc.]( [Role of Immunomodulatory Drug Therapy in a Patient with Refractory Multiple Myeloma]( [Source: Projects In Knowledge, Inc.]( [Treatment of a Relapsing High-Risk Multiple Myeloma Patient]( [Source: Projects In Knowledge, Inc.]( [Newly Diagnosed Metastatic Prostate Cancer Patient]( [Source: Projects In Knowledge, Inc.]( [Castration-Resistant Prostate Cancer Patient with Bone Metastases]( [Source: Projects In Knowledge, Inc.]( [A Patient-Centric, Performance Measures-Based Approach to NSCLC]( [Source: RMEI Medical Education]( [Neurology Mastery in Multiple Sclerosis Case Studies 1]( [Source: Projects In Knowledge, Inc.]( [Outcomes in NSCLC: A Focus on Quality Improvement-Part1]( [Source: RMEI Medical Education]( [Hematology CLL @POC]( [Source: @Point of Care]( More of Today's Stories [Prostate Cancer: Poor Responders Benefit from Taxane Switch]( CME/CE [Will Pruning the Biomedical Field Keep it Alive?]( [Taking Your Daily Dose of News? Here's a Quiz]( [Mediocre Evidence Behind Many Primary Care Decisions]( [Nausea Common with Methotrexate in JIA]( CME/CE [PodMed: A Medical News Roundup From Johns Hopkins]( [D.C. Week: CBO Scores Senate Bill a Win on Deficit, Loss on Coverage]( [The Decay of Beer Froth Revisited: That's Improbable!]( More news from MedPage Today® Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [EverydayHealth] © Copyright 2017 Everyday Health, Inc. All rights reserved. Use of this site constitutes acceptance of the MedPageToday.com [terms of use]( and [privacy policy.]( The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address:{EMAIL} [Manage my e-mail settings]( | [Unsubscribe from "Daily Headlines"](lst=Daily%20Headlines) Technical Questions: feedback@medpagetoday.com 345 Hudson Street 16th Floor New York, NY 10014

Marketing emails from medpagetoday.com

View More
Sent On

30/06/2024

Sent On

30/06/2024

Sent On

29/06/2024

Sent On

29/06/2024

Sent On

28/06/2024

Sent On

28/06/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.